Business Context and Reporting Period
Oragenics, Inc. filed a Form 8-K on May 23, 2018, reporting significant corporate events. The company is incorporated in Florida and operates from Tampa, FL. The filing primarily addresses the issuance of a new U.S. patent and the announcement of pro forma shareholders' equity following a recent capital raise.
Key Financial Metrics
The filing provides specific data regarding shareholders' equity as of March 31, 2018, adjusted for a registered direct offering completed on April 6, 2018.
| Metric | Value (USD) |
|---|---|
| Total Shareholders' Equity (Reported as of March 31, 2018) | $4,315,236 |
| Proceeds from April 6, 2018 Offering | $1,800,000 |
| Pro Forma Total Shareholders' Equity (as of March 31, 2018) | $6,115,236 |
The April 6, 2018 Offering consisted of 900,000 shares of common stock at $2.00 per share and 900,000 warrants at an exercise price of $2.00 per share. The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes
- Capital Structure: Shareholders' equity increased by approximately $1.8 million due to the closing of the registered direct offering.
- Intellectual Property: The company secured U.S. Patent No. 9,964,488 for variants of the lantibiotic MU1140 and other lantibiotics with improved pharmacological properties.
Outlook, Risks, and Management Commentary
Management highlighted the strategic importance of the newly granted patent, which covers methods to treat and prevent infections, diseases, and colonization by bacteria. The pro forma equity figures are presented to reflect the company's financial position after the capital infusion. The filing notes that the pro forma equity figures have not been reviewed by independent auditors. No specific forward-looking guidance, risk factors, or contingencies beyond the standard patent and offering details were disclosed in this specific report.
Investor Verification Checklist
- Verify the status and commercial potential of U.S. Patent No. 9,964,488 regarding lantibiotic variants.
- Confirm the final closing details and use of proceeds from the April 6, 2018 registered direct offering.
- Review the unaudited nature of the pro forma shareholders' equity figures.
- Check subsequent filings for updated revenue and cash flow data, as this 8-K does not contain operational financial results.